Patents Assigned to The United States of America as represented by the Secretary Department of Health & Human Services
  • Publication number: 20200199587
    Abstract: The description provides a molecular switch comprising at least two nanoparticles, wherein a first nanoparticle comprises DNA and/or RNA oligonucleotides, and a second nanoparticle which is complementary to the first nanoparticle comprises reverse complementary DNA and/or RNA oligonucleotides of the first nanoparticle; wherein the complementary nanoparticles interact under physiological conditions leading to thermodynamically driven conformational changes in the first and second nanoparticles leading to their re-association to release one or more duplexes comprising said DNA and/or RNA oligonucleotides and the reverse complementary DNA and/or RNA oligonucleotides, and wherein the nanoparticles are not rings and have no single stranded toeholds.
    Type: Application
    Filed: April 3, 2018
    Publication date: June 25, 2020
    Applicants: The United States of America,as represented by the Secretary,Department of Health and Human Services, The University of North Carolina at Charlotte
    Inventors: Bruce Allen Shapiro, Kirill Andreevich Afonin, Eckart H.U. Bindewald, Mathias D. Viard, Wojciech Kasprzak, Marina A. Dobrovolskaia, Justin R. Halman
  • Patent number: 10687942
    Abstract: Devices and methods are disclosed for the treatment or repair of regurgitant cardiac valves, such as a mitral valve. An annuloplasty device can be placed in the coronary sinus to reshape the mitral valve and reduce mitral valve regurgitation. A protective device can be placed between the annuloplasty device and an underlying coronary artery to inhibit compression of the underlying coronary artery by the annuloplasty device in the coronary sinus. In addition, the protective device can inhibit compression of the coronary artery from inside the heart, such as from a prosthetic mitral valve that exerts radially outward pressure toward the coronary artery. The annuloplasty device can also create an artificial inner ridge or retaining feature projecting into the native mitral valve region to help secure a prosthetic mitral valve.
    Type: Grant
    Filed: April 16, 2018
    Date of Patent: June 23, 2020
    Assignee: THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES
    Inventors: June-Hong Kim, Robert J. Lederman, Ozgur Kocaturk
  • Patent number: 10689456
    Abstract: The invention provides a chimeric antigen receptor (CAR) having antigenic specificity for CD70, the CAR comprising: an antigen binding-transmembrane domain comprising a CD27 amino acid sequence lacking all or a portion of the CD27 intracellular T cell signaling domain; a 4-1BB intracellular T cell signaling domain; a CD3? intracellular T cell signaling domain; and optionally, a CD28 intracellular T cell signaling domain. Nucleic acids, recombinant expression vectors, host cells, populations of cells, and pharmaceutical compositions relating to the CARs are disclosed. Methods of detecting the presence of cancer in a mammal and methods of treating or preventing cancer in a mammal are also disclosed.
    Type: Grant
    Filed: April 9, 2015
    Date of Patent: June 23, 2020
    Assignee: The United States of America, as represented by the Secretary, Department of Health and Human Services
    Inventors: Qiong J. Wang, Zhiya Yu, James C. Yang
  • Patent number: 10683316
    Abstract: The invention provides for the treatment of disorders related to viral infection, using salen manganese compounds.
    Type: Grant
    Filed: November 9, 2012
    Date of Patent: June 16, 2020
    Assignees: The United States of America, as represented by the Secretary, Department of Health and Human Services, Trustees of Boston University
    Inventors: John C. Kash, Jeffery K. Taubenberger, Rodney L. Levine, Susan Doctrow
  • Patent number: 10683270
    Abstract: A compound, or a pharmaceutically acceptable salt or ester thereof, comprising (i) a CB1 receptor mediating scaffold conjugated to (ii) a second therapeutic scaffold.
    Type: Grant
    Filed: August 10, 2017
    Date of Patent: June 16, 2020
    Assignee: The United States of America as represented by the Secretary, Department of Health and Human Services
    Inventors: George Kunos, Malliga Iyer, Resat Cinar, Kenner C. Rice
  • Patent number: 10683277
    Abstract: Described are compounds, which are antagonists of the P2Y14 receptor, for example, a compound of formula (I) in which ring A, R1, R2, R3, and n are as described herein. Also provided are dendron conjugates comprising the compounds, and methods of using the compounds, including a method of treating a disorder, such as inflammation, diabetes, insulin resistance, hyperglycemia, a lipid disorder, obesity, a condition associated with metabolic syndrome, and asthma, and a method of antagonizing P214 receptor activity in a cell.
    Type: Grant
    Filed: September 23, 2016
    Date of Patent: June 16, 2020
    Assignee: The United States of America, as represented by the Secretary, Department of Health and Human Services
    Inventors: Kenneth A. Jacobson, Anna Junker, Elisa Uliassi, Evgeny Kiselev
  • Patent number: 10682379
    Abstract: Pharmaceutical compositions are disclosed that includes a therapeutically effective amount of a purified viable gram negative bacteria and a pharmaceutically acceptable carrier. The pharmaceutical compositions are formulated for topical administration. Methods of treating atopic dermatitis using these pharmaceutical compositions are also disclosed.
    Type: Grant
    Filed: January 16, 2019
    Date of Patent: June 16, 2020
    Assignee: THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES
    Inventors: Ian Antheni Myles, Sandip K. Datta
  • Patent number: 10683362
    Abstract: Mesothelin is a differentiation antigen present on the surface of ovarian cancers, mesotheliomas and several other types of human cancers. Because among normal tissues, mesothelin is only present on mesothelial cells, it represents a good target for antibody mediated delivery of cytotoxic agents. The present invention is directed to improved recombinant immunotoxins comprising anti-mesothelin antibodies, including Fv molecules with particularly high affinity for mesothelin, and a Pseudomonas Exotoxin moiety which has been modified to reduce its immunogenicity and protease sensitivity and providing a better cytotoxicity for cells which express mesothelin. The RITs are well-suited for the treatment of cancers of the ovary, stomach, squamous cells, mesotheliomas and other malignant cells expressing mesothelin.
    Type: Grant
    Filed: May 4, 2012
    Date of Patent: June 16, 2020
    Assignee: The United States of America, as represented by the Secretary, Department of Health and Human Services
    Inventors: Ira H. Pastan, John Weldon, Richard Beers
  • Publication number: 20200184647
    Abstract: Methods include processing image data through a plurality of network stages of a progressively holistically nested convolutional neural network, wherein the processing the image data includes producing a side output from a network stage m, of the network stages, where m>1, based on a progressive combination of an activation output from the network stage m and an activation output from a preceding stage m?1. Image segmentations are produced. Systems include a 3D imaging system operable to obtain 3D imaging data for a patient including a target anatomical body, and a computing system comprising a processor, memory, and software, the computing system operable to process the 3D imaging data through a plurality of progressively holistically nested convolutional neural network stages of a convolutional neural network.
    Type: Application
    Filed: June 8, 2018
    Publication date: June 11, 2020
    Applicant: The United States of America, as represented by the Secretary Department of Health and Human Service
    Inventors: Adam Patrick Harrison, Ziyue Xu, Le Lu, Ronald M. Summers, Daniel Joseph Mollura
  • Publication number: 20200181215
    Abstract: The invention provides Brachyury deletion mutant polypeptides, nucleic acids encoding the polypeptides, non-yeast vectors comprising the nucleic acids, non-yeast cells, and methods of use.
    Type: Application
    Filed: January 31, 2020
    Publication date: June 11, 2020
    Applicant: The United States of America,as represented by the Secretary,Department of Health and Human Services
    Inventors: Jeffrey Schlom, Claudia M. Palena
  • Patent number: 10676528
    Abstract: The invention provides a chimeric antigen receptor (CAR) comprising an antigen binding domain specific for TSLPR, a transmembrane domain, and an intracellular T cell signaling domain. Nucleic acids, recombinant expression vectors, host cells, populations of cells, antibodies, or antigen binding portions thereof, and pharmaceutical compositions relating to the CARs are disclosed. Methods of detecting the presence of a proliferative disorder, e.g., cancer, in a mammal and methods of treating or preventing a proliferative disorder, e.g., cancer, in a mammal are also disclosed.
    Type: Grant
    Filed: October 30, 2014
    Date of Patent: June 9, 2020
    Assignee: The United States of America, as represented by the Secretary, Department of Health and Human Services
    Inventors: Haiying Qin, Terry J. Fry
  • Patent number: 10676475
    Abstract: Provided herein are compounds useful for improving mRNA splicing in a cell. Exemplary compounds provided herein are useful for improving mRNA splicing in genes comprising at least one exon ending in the nucleotide sequence CAA. Methods for preparing the compounds and methods of treating diseases of the central nervous system are also provided.
    Type: Grant
    Filed: January 15, 2016
    Date of Patent: June 9, 2020
    Assignees: The General Hospital Corporation, The United States of America, as Represented by the Secretary, Department of Health and Human Services
    Inventors: Susan A. Slaugenhaupt, Graham Johnson, William D. Paquette, Wei Zhang, Juan Marugan
  • Publication number: 20200171215
    Abstract: Methods are provided for promoting cartilage growth and/or repair. The methods include, administering locally to a site in a subject in need thereof, bone marrow stromal cells attached to fibrin microbeads comprising crosslinked hyaluronic acid and thereby producing stable cartilage locally at the site in the subject.
    Type: Application
    Filed: May 31, 2018
    Publication date: June 4, 2020
    Applicants: THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH & HUMAN SERVICES, HADASIT MEDICAL RESEARCH SERVICES AND DEVELOPMENT LTD.
    Inventors: Pamela Gehron Robey, Sergei Kuznetsov, Raphael Gorodetsky, Astar Hailu-Lazmi, Mitchell Shirvan, Joseph Featherall
  • Patent number: 10669567
    Abstract: The present disclosure provides methods for detecting early Lyme disease. The present disclosure provides a biosignature indicative of the presence or absence of Borrelia burgdorferi infection.
    Type: Grant
    Filed: February 17, 2016
    Date of Patent: June 2, 2020
    Assignees: The United States of America, as represented by the Secretary, Department of Health and Human Services, Colorado State University Research Foundation, New York Medical College
    Inventors: John T. Belisle, Claudia R. Molins, Gary P. Wormser
  • Patent number: 10670610
    Abstract: Disclosed are specific biomarkers that allow for early testing of preeclampsia/HELLP syndrome. Thus, a method is provided predicting preeclampsia in a pregnant woman. Also disclosed is a kit comprising means for assaying a sample from a pregnant woman for the concentrations of the specific biomarkers.
    Type: Grant
    Filed: June 13, 2013
    Date of Patent: June 2, 2020
    Assignees: Wayne State University, The United States of America as represented by The Secretary, Department of Health and Human Services Office of Technology Transfer, National Institutes of Health, Semmelweis University, Genesis Theranostix Korlatolt Felelossegu Tarsasag
    Inventors: Adi L. Tarca, Nandor Than, Gabor Juhasz, Adrienna Katalin Kekesi, Hamutal Meiri, Zoltan Papp, Roberto Romero
  • Patent number: 10669591
    Abstract: A process for detecting Haemophilus influenzae nucleic acid in a sample includes producing an amplification product by amplifying a Haemophilus influenzae nucleotide sequence and measuring the amplification product to detect Haemophilus influenzae in the sample. Some embodiments allow direct serotype determination in a single step assay. Also provided are reagents and methods for detecting and distinguishing Haemophilus influenzae from other infectious agents. A kit is provided for detecting and quantifying Haemophilus influenzae in a sample.
    Type: Grant
    Filed: January 31, 2017
    Date of Patent: June 2, 2020
    Assignee: THE GOVERNMENT OF THE UNITED STATES OF AMERICA AS REPRESENTED BY THE SECRETARY OF THE DEPARTMENT OF HEALTH AND HUMAN SERVICES
    Inventors: Jennifer Thomas, Xin Wang, Cynthia Hatcher, Raydel Anderson, Mary Jordan Theodore, Leonard W. Mayer
  • Patent number: 10668114
    Abstract: Pharmaceutical compositions are disclosed that includes a therapeutically effective amount of a purified viable Gram negative bacteria and a pharmaceutically acceptable carrier. The pharmaceutical compositions are formulated for topical administration. Methods of treating atopic dermatitis using these pharmaceutical compositions are also disclosed.
    Type: Grant
    Filed: February 8, 2019
    Date of Patent: June 2, 2020
    Assignee: THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES
    Inventors: Ian Antheni Myles, Sandip K. Datta
  • Patent number: 10662238
    Abstract: Isolated VHH monoclonal antibodies are disclosed that specifically bind to a Norovirus polypeptide. In some embodiments, the Norovirus is a Genogroup I Norovirus or a Genogroup II Norovirus. In other embodiments, the Norovirus is Norwalk or MD2004 virus. In some embodiments, the monoclonal antibodies specifically bind VP1. Also disclosed are compositions including the disclosed antibodies, nucleic acids encoding these antibodies, expression vectors including the nucleic acids, and isolated host cells that express the nucleic acids. The antibodies and compositions disclosed herein can be used for detecting the presence of a Norovirus in a biological sample, or detecting a Norovirus infection. Also disclosed are methods of treating and/or preventing a NoV infection.
    Type: Grant
    Filed: May 17, 2018
    Date of Patent: May 26, 2020
    Assignees: The United States of America, as represented by the Secretary, Department of Health and Human Services, Instituto Nacional De Technologia Agropecuaria
    Inventors: Karin Bok, Lorena Laura Garaicoechea, Viviana Parreno, Andrea Pamela Aguilar, Marina Bok, Lisbeth Kim Green, Stanislav Vladimirovich Sosnovtsev
  • Publication number: 20200157241
    Abstract: The invention provides chimeric antigen receptors (CARs) comprising an antigen binding domain of human antibody 139, an extracellular hinge domain, a transmembrane domain, and an intracellular domain T cell receptor signaling domain. Nucleic acids, recombinant expression vectors, host cells, populations of cells, antibodies, or antigen binding portions thereof, and pharmaceutical compositions relating to the CARs are disclosed. Methods of detecting the presence of cancer in a host and methods of treating or preventing cancer in a host are also disclosed.
    Type: Application
    Filed: January 24, 2020
    Publication date: May 21, 2020
    Applicant: The United States of America,as represented by the Secretary,Department of Health and Human Services
    Inventors: Richard A. Morgan, Steven A. Rosenberg
  • Patent number: 10653727
    Abstract: Pharmaceutical compositions are disclosed that includes a therapeutically effective amount of a purified viable Gram negative bacteria and a pharmaceutically acceptable carrier. The pharmaceutical compositions are formulated for topical administration. Methods of treating atopic dermatitis using these pharmaceutical compositions are also disclosed.
    Type: Grant
    Filed: July 25, 2019
    Date of Patent: May 19, 2020
    Assignee: THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES
    Inventors: Ian Antheni Myles, Sandip K. Datta